DURECT Corp. is a biopharmaceutical company focused on two areas of active drug development: New therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its epigenomic regulator program. Its drug development expertise is being applied primarily to the fields of pain management, central nervous system disorders, acute organ injury and metabolic diseases such as nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Late-stage development programs include POSIMIR (SABER-bupivacaine) and REMOXY (ORADUR-oxycodone). DURECT's epigenomic regulator program includes the lead molecule DUR-928 in Phase 1 development. DUR-928 is an endogenous small molecule that modulates lipid homeostasis, inflammation and cell survival.

Expert Comments:

Patrick Dolezal, LifeSci Capital (12/13/17)
"Earlier today, DURECT Corp. announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application for Indivior's RBP-7000. . .the company is eligible for $5M upon FDA approval. . .the PDUFA date for RBP-7000 is July 28, 2018."

Analyst Grant Zeng of Zacks Small Cap Research examines what transpired with this biopharmaceutical company during Q3/17.
read more >
Grant Zeng, Zacks Small-Cap Research (11/2/17)
"DURECT Corp. recorded a total revenue of $20.7M in Q3/17 ended Sept. 30, 2017, compared to $3.7M in Q3/16. . .the company reported net income of $6.1M in Q3/17, as compared to a net loss of $8.8M in Q3/16. At Sept. 30, it had cash and investments of $41.8M, which compared to $33.6M at June 30, 2017." -Zacks Small-Cap Research

Francois Brisebois, Laidlaw & Company (11/2/17)
"DURECT Corp. reported its Q3/17 last night after the close, roughly in line with expectations after adjusting for one-time events. . .the company ended Q3/17 with cash and investments of $41.8M, which should be sufficient for the next couple years. . .we believe 2018 could prove to be a pivotal year for DURECT."

Ed Arce, H.C. Wainwright & Co. (11/2/17)
"DURECT Corp. intends to initiate a Phase 2, open-label study with oral DUR-928 in primary sclerosing cholangitis. . .next, the company is currently finalizing the protocol on a Phase 2 study of injectable DUR-928 in patients with moderate to severe acute liver function impairment to assess the safety, pharmacokinetics and pharmacodynamics of several doses of the compound. . .DURECT is also finalizing a study protocol for a Phase 2 proof-of-concept study of topically applied DUR-928."

Grant Zeng, Zacks Small-Cap Research (10/25/17)
"We are especially optimistic about DURECT Corp.'s epigenetic regulator DUR-928, which holds great market potential for multiple indications, including nonalcoholic fatty liver disease/nonalcoholic steatohepatitis and acute kidney injury; multiple Phase 2 trials will be initiated in 2017. We continue to be positive about the company's story." -Zacks Small-Cap Research

Terry Chrisomalis, Biotech Analysis Central (10/23/17)
"DURECT Corp. is now highly attractive as a potential speculative play. That's because it has another drug compound known as DUR-928, which is an orally bioavailable small molecule; it is being tested in three different indications, each of which targets large markets."

A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts.
read more >

More Expert Comments

Experts Following This Company

Ed Arce, Managing Direction and Senior Research Analyst – H.C. Wainwright & Co.
Francois Brisebois, Healthcare Research Analyst – Laidlaw & Company
Patrick Dolezal – LifeSci Capital
Jim Molloy, Analyst
David Sherman, Analyst – LifeSci Capital
Adam Walsh, Analyst-Healthcare – Stifel
Grant Zeng, Senior Biotech Analyst – Zacks Investment Research, Zacks Small-Cap Research

The information provided above is from analysts, newsletters, the company and other contributors.

DURECT Corp. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
DUR-928, in Phase 1, is an Endogenous Small Molecule with Compelling Animal Data
Two Late Stage Pain Products Addressing Large Markets
Company Holds the WW Rights to DUR-928 and POSIMIR
DURECT Corp. Content